MIRA Pharmaceuticals Inc. Company Profile
NASDAQ: MIRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MIRA Pharmaceuticals at a glance
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Miami, FL. MIRA Pharmaceuticals is led by Mr. Erez Aminov. The company's shares have traded publicly since 2023.
At a market capitalization of $31.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001904286, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does MIRA Pharmaceuticals do?
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Business description based on the company's public filings.
Company information
- Legal name
- MIRA Pharmaceuticals Inc.
- Ticker
- NASDAQ: MIRA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Erez Aminov
- Headquarters
- 1200 Brickell Avenue, Miami, FL, United States
- Phone
- 786 432 9792
- Website
- mirapharmaceuticals.com
- IPO year
- 2023
- Market cap
- $31.33M
- SEC CIK
- 0001904286
- Latest annual report
- 10-K · Mar 31, 2026
Companies similar to MIRA Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNAZTransCode Therapeutics Inc. | 1.86 | +8.77% | $31.49M | vs MIRA |
| RMTIRockwell Medical Inc. | 7.89 | -1.62% | $31.80M | vs MIRA |
| NXTCNextCure Inc. | 7.18 | +5.90% | $32.87M | vs MIRA |
| NNVCNanoViricides Inc. | 1.30 | -0.76% | $33.18M | vs MIRA |
| IGCIGC Pharma Inc. | 0.2799 | -1.75% | $28.94M | vs MIRA |
| BCTXBriaCell Therapeutics Corp. | 3.91 | -0.13% | $34.02M | vs MIRA |
| ATNMActinium Pharmaceuticals Inc. (Delaware) | 1.10 | +1.85% | $34.59M | vs MIRA |
| CNTXContext Therapeutics Inc. | 0.3042 | +1.74% | $27.95M | vs MIRA |